European Journal of Chemistry 2010, 1(4), 325-334 | doi: | Get rights and content

Issue cover


QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain

Brij Kishore Sharma (1,*) , Pradeep Pilania (2) , Prithvi Singh (3)

(1) Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
(2) Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
(3) Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
(*) Corresponding Author

Received: 06 Jul 2010 | Revised: 28 Aug 2010 | Accepted: 01 Sep 2010 | Published: 22 Dec 2010 | Issue Date: December 2010


The EP1 receptor inhibitory activity of 1,2-diarylcyclopentene derivatives have been quantitatively analyzed in terms of Dragon descriptors. The derived QSAR models have provided rationales to explain the EP1 receptor inhibitory activity of 1,2-diarylcyclopentene derivatives. The 2D-autocorrelation descriptors (MATS4e, MATS5e, MATS7v, GATS5e and GATS7v) have highlighted the role of atomic properties in respective lags of autocorrelations to explain the biological actions of 1,2-diarylcyclopentene analogues. Presence of fluorine atom (nF) and smaller distance between N and O atoms (T(N..O)) in molecular structures, in addition to Kier-Hall electrotopological states (Ss) have also shown prevalence to optimize the EP1 receptor inhibitory activity. Partial least square analysis has confirmed the dominance of information content of the combinatorial protocol in multiple linear regression identified descriptors. Applicability domain analysis revealed that the suggested model matches the high quality parameters with good fitting power and capability of assessing external data. All the compounds are within the applicability domain of the proposed model and were evaluated correctly.



1,2-Diarylcyclopentenes; EP1 receptor antagonists; Dragon descriptors; QSAR; CP-MLR; Partial least square analysis

Full Text:

PDF    Open Access

DOI: 10.5155/eurjchem.1.4.325-334.195

Links for Article

| | | | | | |

| | | | | | |

| | | |

Related Articles

Article Metrics

icon graph This Abstract was viewed 811 times | icon graph PDF Article downloaded 413 times



[1]. Tawassl Tajelsir Hassan Hajalsiddig, Ahmed Elsadig Mohammed Saeed
QSAR and molecular docking studies on 4-quinoline carboxylic acid derivatives as inhibition of vesicular stomatitis virus replication
European Journal of Chemistry  10(1), 45, 2019
DOI: 10.5155/eurjchem.10.1.45-51.1795

[2]. Mukesh C. Sharma, Smita Sharma, Shivangi Sharma
Computational study of diarylcyclopentene derivatives as selective prostaglandin EP1 receptor antagonist: QSAR approach
Network Modeling Analysis in Health Informatics and Bioinformatics  5(1), , 2016
DOI: 10.1007/s13721-016-0120-y


[1]. Murakami, M.; Nakatani, Y.; Tanioka, T.; Kudo, I. Prostaglandins Other Lipid Mediat. 2002, 68-69, 383-399.

[2]. Claveau, D.; Sirinyan, M.; Guay, J.; Gordon, R.; Chan, C-C.; Bureau, Y.; Riendeau, D.; Mancini, J. A. J. Immunol. 2003, 170, 4738-4744.

[3]. Trebino, C. E.; Stock, J. L.; Gibbons, C. P.; Naiman, B. M.; Wachtmann, T. S.; Umland, J. P.; Pandher, K.; Lapointe, J-M.; Saha, S.; Roach, M. L.; Carter, D.; Thomas, N. A.; Durtschi, B. A.; McNeish, J. D.; Hambor, J. E.; Jakobsson, P-J.; Carty, T. J.; Perez J. R.; Audoly, L. P. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9044-9049.
PMid:12835414    PMCid:166435

[4]. Kamei, D.; Yamakawa, K.; Takegoshi, Y.; Mikami-Nakanishi, M.; Nakatani, Y.; Oh-ishi, S.; Yasui, H.; Azuma, Y.; Hirasawa, N.; Ohuchi, K.; Kawaguchi, H.; Ishikawa, Y.; Ishii, T.; Uematsu, S.; Akira, S.; Murakami, M.; Kudo, I. J. Biol. Chem. 2004, 279, 33684-33695.

[5]. Mabuchi, T.; Kojima, H.; Abe, T.; Takagi, K.; Sakurai, M.; Ohmiya, Y.; Uematsu, S.; Akira, S.; Watanabe, K.; Ito, S. Neuroreport 2004, 15, 1395-1398.

[6]. Camu, F.; Shi, L.; Vanlersberghe, C. Drugs 2003, 63(suppl. 1), 1-7.

[7]. Bianchi, M.; Broggini, M. Drugs 2003, 63(suppl. 1), 37-46.

[8]. Jeger, R. V.; Greenberg, J. D.; Ramanathan, K.; Farkouh, M. E. Exp. Rev. Clin. Immunol. 2005, 1, 37-45.

[9]. Lee, Y.; Rodriguez, C.; Dionne, R. A. Curr. Pharm. Des. 2005, 11, 1737-1755.

[10]. Akarca, U. S. Curr. Pharm. Des. 2005, 11, 1779-1793.

[11]. Sheen, C. L.; MacDonald, T. M. Exp. Opin. Pharmacother. 2002, 3, 265-269.

[12]. Hawkey, C. J.; Jackson, L.; Harper, S. E.; Simon, T. J.; Mortensen, E.; Lines, C. R. Aliment. Pharmacol. Ther. 2001, 15, 1-9.

[13]. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Bosi Ferraz, M.; Hawkey, C. J.; Hochberg, M. C.; Kvien T. K.; Schnitzer, T. J.; VIGOR study group. N. Eng. J. Med. 2000, 343, 1520-1528.

[14]. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. J. Am. Med. Assoc. 2000, 284, 1247-1255.

[15]. Merck & Co. Press Release; 30 September 2004.

[16]. Mukherjee, D.; Nissen, S. E.; Topol, E. J. J. Am. Med. Assoc. 2001, 286, 954-959.

[17]. Mamdani, M.; Juurlink, D. N.; Lee, D. S.; Rochon, P. A.; Kopp, A.; Naglie, G.; Austin, P. C.; Laupacis, A.; Stukel, T. A. Lancet 2004, 363, 1751-1756.

[18]. Scheen, A. J. Rev. Med. Liege 2004, 59, 565-569.

[19]. Bresalier, R. S.; Sandier, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. N. Engl. J. Med. 2005, 352, 1092-1102.

[20]. Solomon, S. D.; McMurray, J. J. V.; Pfeffer, M. A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W. F.; Zauber, A.; Hawk E.; Bertagnolli, M. N. Engl. J. Med. 2005, 352, 1071-1080.

[21]. Fitzgerald, G. A. N. Engl. J. Med. 2004, 351, 1709-1711.

[22]. Lagakos, S. W. N. Engl. J. Med. 2006, 355, 113-117.

[23]. Meagher, E. A. Curr. Pharm. Des. 2004, 10, 603-611.

[24]. Coleman, R. A.; Smith, W. L.; Narumiya, S. Pharmacol. Rev. 1994, 46, 205-229.

[25]. Breyer, R. M.; Bagdassarian, C. K.; Myers, S. A.; Breyer, M. D. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 661-690.

[26]. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Physiol. Rev. 1999, 79, 1193-1226.

[27]. Coleman, R. A.; Kennedy, I.; Humphrey, P. P. A.; Bunce, K.; Lumley, P. Comprehensive Medicinal Chemistry, 3rd volume, Pergamon: Oxford, UK, 1990.

[28]. Hata, A. N.; Breyer, R. M. Pharmacol. Ther. 2004, 103, 147-166.

[29]. Ungrin, M. D.; Carrière, M-C.; Denis, D.; Lamontagne, S.; Sawyer, N.; Stocco, R.; Tremblay, N.; Metters, K. M.; Abramovitz, M. Mol. Pharmacol. 2001, 59, 1446–1455.

[30]. Hallinan, E.; Hagen, T.; Jusa, R.; Tsymbalov, S.; Rao, S.; van Hoeck, J-P.; Rafferty, M.; Stapelfeld, A.; Savage, M.; Reichman, M. J. Med. Chem. 1993, 36, 3293-3299.

[31]. Hallinan, E.; Stapelfeld, A.; Savage, M.; Reichman, M. Bioorg. Med. Chem. Lett. 1994, 4, 509-514.

[32]. Lanthorn, T.; Bianchi, R.; Perkins, W. Drug Dev. Res. 1995, 34, 35–38.

[33]. Novel EP1 receptor antagonists. Expert Opin. Ther. Patents 2004, 14, 435-438.

[34]. Breault, G.A. WO9700863A1, 1997.

[35]. Watanabe, K.; Kawamori, T.; Nakatsugi, S.; Ohta, T.; Ohuchida, S.; Yamamoto, H.; Maruyama, T.; Kondo, K.; Narumiya, S.; Sugimura, T.; Wakabayashi, K. Cancer Lett. 2000, 156, 57-61.

[36]. Ducharme, Y.; Blouin, M.; Carrière, M. C.; Chateauneuf, A.; Côte, B.; Denis, D.; Frenette, R.; Greig, G.; Kargman, S.; Lamontagne, S.; Martins, E.; Nantel, F.; O’Neill, G.; Sawyer, N.; Metters, K. M.; Friesen, R. W. Bioorg. Med. Chem. Lett. 2005, 15, 1155-1160.

[37]. Minami, T.; Nakano, H.; Kobayashi, T.; Sugimoto, Y.; Ushikubi, F.; Ichikawa, A.; Narumiya, S.; Ito, S. Br. J. Pharmacol. 2001, 133, 438-444.
PMid:11375261    PMCid:1572799

[38]. Mebane, H.; Turnbach, M. E.; Randich, A. J. Pain 2003, 4, 392-399.
PMid:11160156    PMCid:199184

[39]. Stock, J. L.; Shinjo, K.; Burkhardt, J.; Roach, M.; Taniguchi, K.; Ishikawa, T.; Kim, H-S.; Flannery, P. J.; Coffman, T. M.; McNeish, J. D.; Audoly, L. P. J. Clin. Invest. 2001, 107, 325-331.

[40]. Omote, K.; Kawamata, T.; Nakayama, Y.; Kawamata, M.; Hazama, K.; Namiki, A. Anesth. Analg. 2001, 92, 233-238.

[41]. Omote, K.; Yamamoto, H.; Kawamata, T.; Nakayama, Y.; Namiki, A. Anesth. Analg. 2002, 95, 1708-1712.

[42]. Kawahara, H.; Sakamoto, T.; Takeda, S.; Onodera, H.; Imaki, J.; Ogawa, R. Anesth. Analg. 2001, 93, 1012-1017.

[43]. Giblin, G. M. P.; Bit, R. A.; Brown, S. H.; Chaignot, H. M.; Chowdhury, A.; Chessell, I. P.; Clayton, N. M.; Coleman, T.; Hall, A.; Hammond, B.; Hurst, D. N.; Michel, A. D.; Naylor, A.; Novelli, R.; Scoccitti, T.; Spalding, D.; Tang, S. P.; Wilson, A. W.; Wilson, R. Bioorg. Med. Chem. Lett. 2007, 17, 385-389.

[44]. SYSTAT, Version 7.0; SPSS Inc., 444 North Michigan Avenue, Chicago, IL, 60611.

[45]. ChemDraw Ultra 6.0 and Chem3D Ultra, Cambridge Soft Corporation, Cambridge, USA.

[46]. Dragon software (version 1.11-2001) by Todeschini R.; Consonni V. Milano, Italy.

[47]. Prabhakar, Y. S. QSAR Comb. Sci. 2003, 22, 583-595.

[48]. Wold, S. Technometrics 1978, 20, 397-405.

[49]. Kettaneh, N.; Berglund, A.; Wold, S. Comput. Stat. Data Anal. 2005, 48, 69-85.

[50]. Stahle, L.; Wold, S. Biomedical Research, Progress in Medicinal Chemistry, vol. 25, Elsevier Science Publishers, BV, 1998.

[51]. Sharma, B. K.; Pilania, P.; Singh, P.; Sharma, S.; Prabhakar, Y. S. Cent. Eur. J. Chem. 2009, 7, 909-922.

[52]. Sharma, B. K.; Pilania, P.; Singh, P. J. Enz. Inhib. Med. Chem. 2009, 24, 607-615.

[53]. Sharma, S.; Sharma, B. K.; Pilania, P.; Singh, P.; Prabhakar, Y. S. J. Enz. Inhib. Med. Chem. 2009, 24, 1024-1033.

[54]. Sharma, B. K.; Pilania, P.; Singh, P.; Prabhakar, Y. S. SAR QSAR Environ. Res. 2010, 21, 169-185.

[55]. Sharma, B. K.; Pilania, P.; Sarbhai, K.; Singh, P.; Prabhakar, Y. S. Mol. Divers. 2010, 14, 371-384.

[56]. Akaike, H. Second international symposium on information theory, Akademiai Kiado, Budapest, 1973.

[57]. Akaike, H. IEEE Trans. Automat. Contr. 1974, AC-19, 716-723.

[58]. Kubinyi, H. Quant. Struct.-Act. Relat. 1994, 13, 285-294.

[59]. Kubinyi, H. Quant. Struct.-Act. Relat. 1994, 13, 393-401.

[60]. Friedman, J. Technical report no. 102. Laboratory for computational statistics. Stanford University, Stanford, 1990.

[61]. So, S. -S.; Karplus, M. J. Med. Chem. 1997, 40, 4347-4359.

[62]. Prabhakar, Y. S.; Solomon, V. R.; Rawal, R. K.; Gupta, M. K.; Katti, S. B. QSAR Comb. Sci. 2004, 23, 234-244.

[63]. Gramatica, P. QSAR Comb. Sci. 2007, 26, 694-701.

[64]. Golbraikh, A.; Tropsha, A. J. Mol. Graph. Model. 2002, 20, 269-276.

How to cite

Sharma, B.; Pilania, P.; Singh, P. Eur. J. Chem. 2010, 1(4), 325-334. doi:10.5155/eurjchem.1.4.325-334.195
Sharma, B.; Pilania, P.; Singh, P. QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain. Eur. J. Chem. 2010, 1(4), 325-334. doi:10.5155/eurjchem.1.4.325-334.195
Sharma, B., Pilania, P., & Singh, P. (2010). QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain. European Journal of Chemistry, 1(4), 325-334. doi:10.5155/eurjchem.1.4.325-334.195
Sharma, Brij, Pradeep Pilania, & Prithvi Singh. "QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain." European Journal of Chemistry [Online], 1.4 (2010): 325-334. Web. 25 Sep. 2021
Sharma, Brij, Pilania, Pradeep, AND Singh, Prithvi. "QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain" European Journal of Chemistry [Online], Volume 1 Number 4 (22 December 2010)

The other citation formats (EndNote | Reference Manager | ProCite | BibTeX | RefWorks) for this article can be found online at: How to cite item

DOI Link:

CrossRef | Scilit | GrowKudos | Researchgate | Publons | Microsoft | scibey | Scite | Lens | OUCI

WorldCat Paperbuzz | LibKey Citeas | Dimensions | Semanticscholar | Plumx | Kopernio | Zotero | Mendeley

ZoteroSave to Zotero MendeleySave to Mendeley

European Journal of Chemistry 2010, 1(4), 325-334 | doi: | Get rights and content


  • There are currently no refbacks.

Copyright (c)

© Copyright 2010 - 2021  Atlanta Publishing House LLC All Right Reserved.

The opinions expressed in all articles published in European Journal of Chemistry are those of the specific author(s), and do not necessarily reflect the views of Atlanta Publishing House LLC, or European Journal of Chemistry, or any of its employees.

Copyright 2010-2021 Atlanta Publishing House LLC. All rights reserved. This site is owned and operated by Atlanta Publishing House LLC whose registered office is 2850 Smith Ridge Trce Peachtree Cor GA 30071-2636, USA. Registered in USA.